Literature DB >> 25787162

Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision.

Radhika K Smith1, Robert D Fry, Najjia N Mahmoud, E Carter Paulson.   

Abstract

PURPOSE: While the standard of care for patients with rectal cancer who sustain a complete clinical response (cCR) to chemoradiotherapy (CRT) remains proctectomy with total mesorectal excision, data suggests that non-operative management may be a safe alternative. The purpose of this study is to compare outcomes between patients treated with CRT that attained a cCR and opted for a vigilant surveillance to those of the patients who had a complete pathologic response (cPR) following proctectomy.
METHOD: This is a retrospective review of patients treated for adenocarcinoma of the rectum who achieved either a cCR or a cPR following CRT. Patients with a cCR were enrolled in an active surveillance program which included regularly scheduled exams, proctoscopy, serum carcinoembryonic antigen (CEA), endorectal ultrasound, and cross-sectional imaging. Outcomes were compared to those patients who underwent proctectomy with a cPR. Our primary outcome measures were post-treatment complications, recurrence, and survival.
RESULTS: We reviewed 18 patients who opted for surveillance after cCR and 30 patients who underwent proctectomy after a cPR. No non-operative patients had a documented treatment complication, while 17 patients with cPR suffered significant morbidity. There were two recurrences in the active surveillance group, one local and once distant, both treated by salvage resection with no associated mortality at 54 and 62 months. In the cPR group, one patient had a distant recurrence 24 months after surgery which was managed non-operatively. This patient died of unrelated causes 35 months after surgery.
CONCLUSIONS: Active surveillance can be a safe option that avoids the morbidity associated with proctectomy and preserves oncologic outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 25787162     DOI: 10.1007/s00384-015-2165-2

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  18 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program.

Authors:  W E Longo; K S Virgo; F E Johnson; T P Wade; A M Vernava; M A Phelan; W G Henderson; J Daley; S F Khuri
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

4.  Radical and nerve-preserving surgery for rectal cancer in The Netherlands: a prospective study on morbidity and functional outcome.

Authors:  C P Maas; Y Moriya; W H Steup; G M Kiebert; W M Kranenbarg; C J van de Velde
Journal:  Br J Surg       Date:  1998-01       Impact factor: 6.939

5.  Surgical lateral clearance in resected rectal carcinomas: a multivariate analysis of clinicopathologic features.

Authors:  R J Heald; J K MacFarlane; R D Ryall
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

Review 6.  Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma.

Authors:  P Luna-Pérez; S Rodríguez-Ramírez; J Vega; E Sandoval; S Labastida
Journal:  Rev Invest Clin       Date:  2001 Sep-Oct       Impact factor: 1.451

7.  Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04.

Authors:  Marcia M Russell; Patricia A Ganz; Samia Lopa; Greg Yothers; Clifford Y Ko; Amit Arora; James N Atkins; Nathan Bahary; Gamini S Soori; John M Robertson; Janice Eakle; Benjamin T Marchello; Timothy F Wozniak; Robert W Beart; Norman Wolmark
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

8.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

9.  Morbidity and mortality following abdominoperineal resection for rectal adenocarcinoma.

Authors:  N J Petrelli; S Nagel; M Rodriguez-Bigas; M Piedmonte; L Herrera
Journal:  Am Surg       Date:  1993-07       Impact factor: 0.688

10.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

View more
  20 in total

Review 1.  Complete radiotherapy response in rectal cancer: A review of the evidence.

Authors:  Daniel G Couch; David M Hemingway
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 2.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

3.  Systematic review and meta-analysis on outcomes of salvage therapy in patients with tumour recurrence during 'watch and wait' in rectal cancer.

Authors:  J On; J Shim; E H Aly
Journal:  Ann R Coll Surg Engl       Date:  2019-03-11       Impact factor: 1.891

4.  Nonoperative Management or 'Watch and Wait' for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal.

Authors:  Tarik Sammour; Brandee A Price; Kate J Krause; George J Chang
Journal:  Ann Surg Oncol       Date:  2017-03-21       Impact factor: 5.344

Review 5.  'Watch and wait' in rectal cancer: summary of the current evidence.

Authors:  Jason On; Emad H Aly
Journal:  Int J Colorectal Dis       Date:  2018-07-05       Impact factor: 2.571

Review 6.  Can less be more? Organ preservation strategies in the management of rectal cancer.

Authors:  F Rouleau-Fournier; C J Brown
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

7.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

8.  Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or "watch and wait".

Authors:  Chien-Liang Lai; Mei-Ju Lai; Chang-Chieh Wu; Shu-Wen Jao; Cheng-Wen Hsiao
Journal:  Int J Colorectal Dis       Date:  2015-11-25       Impact factor: 2.571

9.  Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.

Authors:  Eisar Al-Sukhni; Kristopher Attwood; David M Mattson; Emmanuel Gabriel; Steven J Nurkin
Journal:  Ann Surg Oncol       Date:  2015-12-14       Impact factor: 5.344

Review 10.  Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project.

Authors:  Mauro Podda; Patricia Sylla; Gianluca Baiocchi; Michel Adamina; Vanni Agnoletti; Ferdinando Agresta; Luca Ansaloni; Alberto Arezzo; Nicola Avenia; Walter Biffl; Antonio Biondi; Simona Bui; Fabio C Campanile; Paolo Carcoforo; Claudia Commisso; Antonio Crucitti; Nicola De'Angelis; Gian Luigi De'Angelis; Massimo De Filippo; Belinda De Simone; Salomone Di Saverio; Giorgio Ercolani; Gustavo P Fraga; Francesco Gabrielli; Federica Gaiani; Mario Guerrieri; Angelo Guttadauro; Yoram Kluger; Ari K Leppaniemi; Andrea Loffredo; Tiziana Meschi; Ernest E Moore; Monica Ortenzi; Francesco Pata; Dario Parini; Adolfo Pisanu; Gilberto Poggioli; Andrea Polistena; Alessandro Puzziello; Fabio Rondelli; Massimo Sartelli; Neil Smart; Michael E Sugrue; Patricia Tejedor; Marco Vacante; Federico Coccolini; Justin Davies; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-07-02       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.